A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype-negative long QT syndrome

BACKGROUND Genetic screening of Long QT syndrome (LOTS) fails to identify disease-causing mutations in about 30% of patients. So far, molecular screening has focused mainly on coding sequence mutations or on substitutions at canonical splice sites. OBJECTIVE The purpose of this study was to explore the possibility that intronic variants not at canonical splice sites might affect spticing regulatory elements, Lead to aberrant transcripts, and cause LQTS. METHOD Molecular screening was performed through DHPLC and sequence analysis. The role of the intronic mutation identified was assessed with a hybrid minigene splicing assay. RESULTS A three-generation LOTS family was investigated. Molecular screening failed to identify an obvious disease-causing mutation in the coding sequences of the major LOTS genes but revealed an intronic A-to-G substitution in KCNH2 (IVS9-28A/G) cosegregating with the clinical phenotype in family members. In vitro analysis proved that the mutation disrupts the acceptor splice site definition by affecting the branch point (BP) sequence and promoting intron retention. We further demonstrated a tight functional relationship between the BP and the polypyrimidine tract, whose weakness is responsible for the pathological effect of the IV59-28A/G mutation. CONCLUSIONS We identified a novel BP mutation in KCNH2 that disrupts the intron 9 acceptor splice site definition and causes LQT2. The present finding demonstrates that intronic mutations affecting pre-mRNA processing may contribute to the failure of traditional molecular screening in identifying disease-causing mutations in LOTS subjects and offers a rationale strategy for the reduction of genotype-negative cases.